Nicole Vitullo's Net Worth

$297 Million

Who is Nicole Vitullo?

Nicole Vitullo has an estimated net worth of $297 Million. This is based on reported shares across multiple companies, which include Dicerna Pharmaceuticals Inc, Volcano Corp, Bionano Genomics, Inc., Orexigen Therapeutics, Inc., ZOGENIX, INC., CoLucid Pharmaceuticals, Inc., TANDEM DIABETES CARE INC, MARINUS PHARMACEUTICALS INC, GLAUKOS Corp, VERACYTE, INC., Atara Biotherapeutics, Inc., Aldeyra Therapeutics, Inc., Vanda Pharmaceuticals Inc., Syndax Pharmaceuticals Inc, Esperion Therapeutics, Inc., Clovis Oncology, Inc., NUVASIVE INC, Alliqua BioMedical, Inc., OBALON THERAPEUTICS INC, Evoke Pharma Inc, aTYR PHARMA INC, ALIMERA SCIENCES INC, OTONOMY, INC., Neothetics, Inc., NOVACEA INC, Durata Therapeutics, Inc., Ocera Therapeutics, Inc., CADENCE PHARMACEUTICALS INC, Achaogen Inc, Regado Biosciences Inc, ACHILLION PHARMACEUTICALS INC, Celator Pharmaceuticals Inc, Somaxon Pharmaceuticals, Inc., Northstar Neuroscience, Inc., and ONYX PHARMACEUTICALS INC.

SEC CIK

Nicole Vitullo's CIK is 0001196863

Past Insider Trading and Trends

2014 was Nicole Vitullo's most active year for acquiring shares with 40 total transactions. Nicole Vitullo's most active month to acquire stocks was the month of October. 2014 was Nicole Vitullo's most active year for disposing of shares, totalling 76 transactions. Nicole Vitullo's most active month to dispose stocks was the month of October. 2011 saw Nicole Vitullo paying a total of $26,590,082.18 for 7,519,108 shares, this is the most they've acquired in one year. In 2020 Nicole Vitullo cashed out on 3,726,972 shares for a total of $21,766,323.60, their largest year based on trade value.